These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35496955)

  • 1. Prognostic Role of Interim 18-Fluorodeoxyglucose-PET in Diffuse Large B Cell Lymphoma: Experience from a Tertiary Care Centre in North India.
    Kumar S; Gupta A; Ora M; Rahman K; Sanjeev ; Choudhary R; Nityanand S
    Indian J Hematol Blood Transfus; 2022 Apr; 38(2):211-222. PubMed ID: 35496955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim
    Jiang M; Chen P; Ruan X; Ye X; Pan Y; Zhang J; Huang Q; Zhou W; Wu H; Wang Q
    Oncol Lett; 2017 Dec; 14(6):6715-6723. PubMed ID: 29344120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of baseline
    Zhu L; Meng Y; Guo L; Zhao H; Shi Y; Li S; Wang A; Zhang X; Shi J; Zhu J; Xu K
    Oncol Lett; 2021 Feb; 21(2):132. PubMed ID: 33552253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index.
    Sun H; Yu Z; Ma N; Zhou J; Tian R; Zhao M; Wang T
    Cancer Manag Res; 2019; 11():9449-9457. PubMed ID: 31807074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
    Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
    Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Kitajima K; Okada M; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Tamaki H; Fujimori Y; Ueda S; Kawamoto H; Taniguchi J; Yamakado K
    Oncotarget; 2019 Sep; 10(52):5403-5411. PubMed ID: 31534626
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.
    Kong Y; Qu L; Li Y; Liu D; Lv X; Han J
    Medicine (Baltimore); 2016 Feb; 95(6):e2808. PubMed ID: 26871850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
    Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
    BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
    Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
    Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
    Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
    J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Values of Different Evaluation Criteria of Interim
    Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma.
    Jo JH; Chung HW; Kim SY; Lee MH; So Y
    Nucl Med Mol Imaging; 2023 Feb; 57(1):26-33. PubMed ID: 36643943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
    Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
    Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.